November 1, 2010 Bulletin #126 ISSN 1923-077X

SASKATCHEWAN FORMULARY BULLETIN

Update to the 60th Edition of the Saskatchewan Formulary

| Product | DIN | Unit Price (\$) |
|-------------------------------------|------------------------|-----------------|
| Full Formulary Listings Effective | e November 1, 2010: | |
| Cosopt PF (dorzolamide HCl/tim | olol maleate) (MSD) | |
| 2%/0.5% ophthalmic solution | 02258692 | 30.8300 |
| Kadian (morphine) (ABB) | | |
| 10mg sustained release capsule | 02242163 | 0.3911 |
| Exception Drug Status (EDS) Lis | tings Effective Novem | ber 1, 2010: |
| Prezista (darunavir) (JAN) | | |
| 75mg tablet | 02338432 | 1.8644 |
| Note: Criteria is included in the R | evisions section below | |

Exception Drug Status (EDS) Criteria Revisions Effective November 1, 2010:

Orencia (abatacept) 250mg powder for solution (BMY)

- (a) For the treatment of active rheumatoid arthritis in patients who have failed or are intolerant to methotrexate and leflunomide.
- Note: This drug should NOT be used in combination with anti-TNF agents.
- (b) For the treatment of juvenile idiopathic arthritis in children who are intolerant to, or have not had an adequate response from etanercept. Initial treatment should be limited to a maximum of 16 weeks. Retreatment should only be permitted for children who had an adequate initial treatment response and subsequently experience a disease flare.

Prezista (darunavir) 75mg, 300mg, 400mg, 600mg tablet (JAN)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

| Product | DIN | Unit Price (\$) |
|---|--|--|
| Full Formulary Listings Effe | ective September 20, 2010: | |
| CanesOral (fluconazole) (BC | CD) | |
| 150mg capsule | 02311690 | 15.9400 |
| CanesOral Combi-Pak (fluc | onazole/clotrimazole) (BCD) | |
| 150mg capsule/1% cream | 02311739 | 18.2200 |
| Interchangeable Full Formu | lary Listings Effective Septembe | er 20, 2010: |
| pms-Carbamazepine Chewt | abs (carbamazepine) (PMS) | |
| 200mg chewable tablet | 02231540 | 0.1520 |
| Sandoz Carbamazepine Che | ewtabs (carbamazepine) (SDZ) | |
| 200mg chewable tablet | 02261863 | 0.1520 |
| Taro-Carbamazepine Chew | tabs (carbamazepine) (TAR) | |
| 200mg chewable tablet | 02244404 | 0.1520 |
| Tegretol Chewtabs (carbama | zepine) (NVR) | |
| 200mg chewable tablet | 02231540 | 0.3331 |
| 200mg chewable tablet | 02231340 | 0.5551 |
| | lary Listings Effective Septembe | |
| Interchangeable Full Formu listed under EDS): | lary Listings Effective Septembe | |
| Interchangeable Full Formu | lary Listings Effective Septembe | |
| Interchangeable Full Formu listed under EDS): Mylan-Carbamazepine CR (| lary Listings Effective Septembe | er 20, 2010 (that were previously |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet | lary Listings Effective September (carbamazepine) (MYL) 02241882 02241883 | er 20, 2010 (that were previously 0.1887 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet | lary Listings Effective September (carbamazepine) (MYL) 02241882 02241883 | er 20, 2010 (that were previously 0.1887 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) | 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet 400mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 | 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 | 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet Sandoz Carbamazepine CR 200mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) | 0.1887 0.3774 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) 02261839 02261847 | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet 400mg | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) 02261839 02261847 | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet 400mg CR tablet 400mg CR tablet 400mg CR tablet 400mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) 02261839 02261847 arbamazepine) (DOM) | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet 400mg CR tablet 400mg CR tablet 400mg CR tablet Dom-Carbamazepine CR (ca 200mg CR tablet 200mg CR tablet 200mg CR tablet 200mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) 02261839 02261847 arbamazepine) (DOM) 02238222 02238223 | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet 400mg CR tablet 400mg CR tablet Dom-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet | (carbamazepine) (MYL) 02241882 02241883 rbamazepine) (PMS) 02231543 02231544 (carbamazepine) (SDZ) 02261839 02261847 arbamazepine) (DOM) 02238222 02238223 | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 |
| Interchangeable Full Formulisted under EDS): Mylan-Carbamazepine CR (200mg CR tablet 400mg CR tablet pms-Carbamazepine CR (ca 200mg CR tablet 400mg CR tablet Sandoz Carbamazepine CR (200mg CR tablet 400mg CR tablet 600mg CR tablet 600mg CR (carbamazepine) | (carbamazepine) (MYL) | 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 0.1887 0.3774 0.1981 0.3963 |

Erythropoiesis Stimulating Agents (ESAs):

Epoetin alfa (Eprex) is the primary erythropoiesis stimulating agent for Saskatchewan Health beneficiaries when treating anemia related to chronic renal failure. The EDS criteria for Eprex and Aranesp is as follows:

Eprex (epoetin alfa) 1,000 IU/0.5mL, 2,000IU/0.5mL, 3,000IU/0.3mL, 4,000IU/0.4mL, 5,000IU/0.5mL, 6,000IU/0.6mL, 8,000IU/0.8mL, 10,000IU/mL, 20,000IU/0.5mL pre-filled syringe (JAN)

For treatment of:

- (a) Anemia in chronic renal disease patients prior to initiation of dialysis.

 Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.
- (b) Anemia in AIDS patients.
- (c) Anemia in transplant patients.

Aranesp (darbepoetin alfa) 25ug/mL (0.4mL), 40ug/mL (0.5mL), 100ug/mL (0.3mL, 0.4mL, 0.5mL), 200ug/mL (0.3mL, 0.4mL, 0.5mL), 500ug/mL (0.3mL, 0.4mL) pre-filled syringe (AMG)

For treatment of anemia in chronic renal disease patients prior to initiation of dialysis. Note: Coverage for dialysis patients is provided under the S.A.I.L. Program. EDS coverage is not required for S.A.I.L. patients.

EXPANSION

MEDICATION ASSESSMENT AND COMPLIANCE PACKAGING POLICY AND PROCEDURE

Effective October 1, 2010:

The fees for medication assessment and compliance packaging have been expanded to include a defined group of mental health clients. Eligible clients will be identified by Health Region Mental Health and Addictions outpatients programs and referred to pharmacies for medication assessment / compliance packaging. Clients residing in an approved group home or institution are NOT eligible.

Reminder:

The Medication Assessment Fee (MAF) remunerates pharmacies for assessing a patient's ability to administer their medications, appropriateness of the medication and dosing intervals, potential interactions, side effects, drug allergies, contraindications and includes communication with the physician and/or health care professional(s) to resolve discrepancies that exist, and potential or actual drug related problems identified. The expectation is that a medication assessment is completed prior to billing the compliance packaging fee.

The Compliance Packaging Fee (CPF) will remunerate pharmacies for services where devices or packaging systems are used to organize doses of one or more solid oral medications (tablets or capsules) according to the time of administration.

Attached is the 10-page Policy and Procedure for insertion into your DPEBB Pharmacy Reference Manual. The Health Region Director of Mental Health and Addictions (or designate) MUST refer the client to the pharmacy for compliance packaging by fax. This form will be used as the prior approval request that pharmacists will complete and then fax to the Drug Plan and Extended Benefits Branch. Both the Health Region Mental Health and Addictions programs and the Pharmacists' Association of Saskatchewan were given opportunity to review documents and provide input.

BILLING PROCEDURE

Please refer to pages 5 and 6 of the policy document for further details. Pharmacies should be able to bill the two fees through the Drug Plan using the Practice Management System. Please contact your pharmacy software vendor if you are unsure how to do this.

WEB PAGE


If you are unable to bill the fees electronically through your Practice Management System, you can use the secure Drug Plan WEB page by logging on to https://www.drugplan.health.gov.sk.ca.

All pharmacies should have updated WEB certificates on a dedicated computer. If you are not sure how to install the WEB certificate, please contact your pharmacy software vendor. To use the WEB page, refer to the DPEBB Pharmacy Reference Manual, Section VI.

QUESTIONS

For questions related to BILLING PROCEDURE you may contact the Drug Plan and Extended Benefits Branch at 1-800-667-7578 or in Regina at 306-787-3315.

For questions related to **POLICY and PROFESSIONAL PRACTICE**, please contact Myla Wollbaum at PAS at 306-359-7277.



Pharmacy Information Bulletin #483 September 20, 2010

FORMULARY LISTINGS TO HELP ADDRESS DRUG SHORTAGES

To address some of the recent and ongoing drug shortages, the following changes and additions to the Formulary will be implemented effective September 20, 2010.

carbamazepine, chewable tablet, 200mg (Tegretol-NVR) (pms-Carbamazepine Chewtab-PMS) (Sandoz Carbamazepine Chew-SDZ) (Taro-Carbamazepine Chewable-TAR) will be added as a Full Formulary listing

| pms-Carbamazepine Chewtabs | 02231540 | 0.1520 | I/C - ~Oct 25 |
|-------------------------------|----------|--------|-----------------|
| Sandoz Carbamazepine Chewtabs | 02261863 | 0.1520 | I/C - ~Nov 18 |
| Taro-Carbamazepine Chewtabs | 02244404 | 0.1520 | I/C - ~Sept 22 |
| Tegretol Chewtabs | 00665088 | 0.3331 | I/C - ~ Sept 30 |

The Drug Plan has confirmed with manufacturers that some brands are available immediately while others will be available in the coming weeks.

carbamazepine, controlled release tablet, 200mg, 400mg (Tegretol CR-NVR) (pms-Carbamazepine-CR-PMS) (Dom-Carbamazepine CR-DOM) (Mylan-Carbamazepine CR-MYL) will be moved from Exception Drug Status (EDS) to a Full Formulary listing 200mg Controlled Release Tablet:

| pms-Carbamazepine CR | 02231543 | 0.1887 | I/C |
|----------------------------------|----------|--------|-----|
| Mylan-Carbamazepine CR | 02241882 | 0.1887 | I/C |
| Sandoz Carbamazepine CR | 02261839 | 0.1887 | I/C |
| Dom-Carbamazepine CR | 02238222 | 0.1981 | I/C |
| Tegretol CR | 00773611 | 0.4135 | I/C |
| 400mg Controlled Release Tablet: | | | |
| pms-Carbamazepine CR | 02231544 | 0.3774 | I/C |
| Mylan-Carbamazepine CR | 02241883 | 0.3774 | I/C |
| Sandoz Carbamazepine CR | 02261847 | 0.3774 | I/C |
| Dom-Carbamazepine CR | 02238223 | 0.3963 | I/C |
| Tegretol CR | 00755583 | 0.8269 | I/C |

- fluconazole, capsule, 150mg (Canesoral-BCD) will be added as a Full Formulary listing CanesOral
 02311690
 15.9400

folic acid, tablet, 1mg (Folic acid-WNP, PHM, VTH, WAM, JAM) will b
 added as a Full Formulary listing for a period of six (6) months from September 20, 2010 to March 31, 2011.

| ing tablet. | | | | |
|-------------|----------|-----|--------|-----|
| Folic acid | 80000274 | WNP | 0.0263 | I/C |
| Folic acid | 02048841 | PHM | 0.0300 | I/C |
| Folic acid | 02245308 | WNP | 0.0309 | I/C |
| Folic acid | 02239882 | PHM | 0.0318 | I/C |
| Folic acid | 00647039 | VTH | 0.0335 | I/C |
| Folic acid | 02236747 | WAM | 0.0314 | I/C |
| Folic acid | 00318973 | JAM | 0.0398 | I/C |

NOTE: The listing of folic acid 1mg tablets is intended to replace folic acid 5mg tablets for those individuals requiring a therapeutic dose of folic acid. If supplies of folic acid 5mg tablets become available during this six-month period, pharmacies should resume dispensing the 5mg dosage form, and the 1mg tablet listing will be discontinued. If the shortage continues to exist at the end of the six-month period, 1mg tablets will continue to be listed.

<u>NOTE:</u> The Drug Identification Numbers (DINs) and Natural Product Numbers (NPNs) listed above have been benefits for Plan Three patients in the past. Effective September 20, 2010, these DINs and NPNs will be listed as Full Formulary benefits. Additional DINs and NPNs will not be added.

COMPOUNDS AND DRUG SHORTAGES

As a reminder, not all compounds are benefits under the Drug Plan and Extended Benefits (DPEB) program.


If a pharmaceutical product is not available and you wish to determine if a compound alternative is eligible to be billed as a benefit, please:

- 1) contact the Drug Plan at 1-800-667-7578 (or 787-3315)
- 2) provide the name, DIN of the pharmaceutical product that is not available and how the compound will be prepared

The Drug Plan will verify the product shortage, review the compound formulation and inform the pharmacy of the corresponding decision. Pharmacies that have been approved to submit a requested compound electronically for adjudication as a benefit may use the pseudoDIN 00990019.

FORMULARY BULLETIN AND STICKER UPDATE

The next formulary bulletin and sticker update is scheduled for November 1, 2010.



Pharmacy Information Bulletin # 485 September 30, 2010

Formulary & Exception Drug Status (EDS) Updates

| Effective September 1, | 2010, the following produc | cts were listed | as benefits in | Saskatch | ewan: |
|-------------------------|----------------------------|------------------|----------------|-----------|---------|
| *Atorvastatin | | | | | |
| Atorvastatin | 10mg tablet | 02348624 | 0.5824 | RPH | I/C |
| Atorvastatin | 20mg tablet | 02348632 | 0.7280 | RPH | I/C |
| Atorvastatin | 40mg tablet | 02348640 | 0.7825 | RPH | I/C |
| Atorvastatin | 80mg tablet | 02348659 | 0.7825 | RPH | I/C |
| Lancet | | | | | |
| One Touch Delica | lancet | 97799501 | 0.0737 | LSN | Non I/C |
| Effective October 1, 20 | 10, the following products | will be listed a | as benefits in | Saskatche | ewan: |
| *5-Aminosalicylic acid | | | | | |
| 5-Aminosalicylic acid | 400mg tablet | 02351463 | 0.3960 | SAN | I/C |
| *Alendronate sodium | | | | | |
| Alendronate | 70mg tablet | 02352966 | 5.5750 | SAN | I/C EDS |
| *Amoxicillin | | | | | |
| Amoxicillin Chew Tab | 250mg chew tablet | 02352737 | 0.6138 | SAN | I/C |
| *Azathioprine | | | | | |
| Azathioprine | 50mg tablet | 02343002 | 0.5418 | SAN | I/C |
| *Cilazapril | | | | | |
| Cilazapril | Img tablet | 02350963 | 0.3717 | SAN | I/C |
| Cilazapril | 2.5mg tablet | 02350971 | 0.4284 | SAN | I/C |
| Cilazapril | 5mg tablet | 02350998 | 0.4977 | SAN | I/C |
| *Ciprofloxacin | | | | | |
| Ciprofloxacin | 250mg tablet | 02353318 | 1.3992 | SAN | I/C EDS |
| Ciprofloxacin | 500mg tablet | 02353326 | 1.5786 | SAN | I/C EDS |
| Ciprofloxacin | 750mg tablet | 02353334 | 2.9774 | SAN | I/C EDS |
| *Cyclobenzaprine HCl | | | | | |
| Cyclobenzaprine | 10mg tablet | 02287064 | 0.3765 | SAN | I/C EDS |
| *Diclofenac sodium | | | | | |
| Diclofenac Sodium SR | 75mg SR tablet | 02352400 | 0.5706 | SAN | I/C |
| *Etidronate Disodium/ | Calcium Carbonate | | | | |
| Etidrocal | 400mg/1250mg tablet | 02353210 | 29.9900 | SAN | I/C |

| *Fenofibrate | | | | | |
|-------------------|---------------|----------|--------|-----|---------|
| Fenofibrate Micro | 200mg capsule | 02286092 | 1.0890 | SAN | I/C |
| *Lamotrigine | | | | | |
| Lamotrigine | 25mg tablet | 02343010 | 0.2088 | SAN | I/C |
| Lamotrigine | 100mg tablet | 02343029 | 0.8354 | SAN | I/C |
| Lamotrigine | 150mg tablet | 02343037 | 1.2530 | SAN | I/C |
| *Leflunomide | | | | | |
| Leflunomide | 10mg tablet | 02351668 | 6.0417 | SAN | I/C EDS |
| Leflunomide | 20mg tablet | 02351676 | 6.0417 | SAN | I/C EDS |
| *Levetiracetam | | | | | |
| Levetiracetam | 250mg tablet | 02353342 | 1.1175 | SAN | I/C |
| Levetiracetam | 500mg tablet | 02353350 | 1.3650 | SAN | I/C |
| Levetiracetam | 750mg tablet | 02353369 | 1.9425 | SAN | I/C |
| *Lovastatin | | | | | |
| Lovastatin | 40mg tablet | 02353237 | 2.0117 | SAN | I/C |
| *Meloxicam | | | | | |
| Meloxicam | 7.5mg capsule | 02353148 | 0.4914 | SAN | I/C EDS |
| Meloxicam | 15mg capsule | 02353156 | 0.5670 | SAN | I/C EDS |
| *Minocycline | | | | | |
| Minocycline | 50mg capsule | 02287226 | 0.5350 | SAN | I/C EDS |
| Minocycline | 100mg capsule | 02287234 | 1.0332 | SAN | I/C EDS |
| *Nabumetone | | | | | |
| Nabumetone | 500mg tablet | 02343282 | 0.5025 | SAN | I/C EDS |
| *Olanzapine | | | | | |
| Sandoz Olanzapine | 2.5mg tablet | 02310341 | 0.8986 | SDZ | I/C EDS |
| Sandoz Olanzapine | 5mg tablet | 02310368 | 1.7922 | SDZ | I/C EDS |
| Sandoz Olanzapine | 7.5mg tablet | 02310376 | 2.6958 | SDZ | I/C EDS |
| Sandoz Olanzapine | 10mg tablet | 02310384 | 3.5944 | SDZ | I/C EDS |
| Sandoz Olanzapine | 15mg tablet | 02310392 | 5.3916 | SDZ | I/C EDS |
| *Omeprazole | | | | | |
| Omeprazole | 20mg capsule | 02348691 | 1.1000 | SAN | I/C EDS |
| *Paroxetine HCl | | | | | |
| Paroxetine | 10mg tablet | 02282844 | 1.0430 | SAN | I/C |
| *Propafenone HCl | | | | | |
| Propafenone | 150mg tablet | 02343053 | 0.4275 | SAN | I/C |
| Propafenone | 300mg tablet | 02343061 | 0.7537 | SAN | I/C |
| | - | | | | |

| *Quetiapine | | | | | |
|--|----------------------------|----------------------|--------|------------|----------------------|
| Quetiapine | 25mg tablet | 02353164 | 0.3458 | SAN | I/C |
| Quetiapine | 100mg tablet | 02353172 | 0.9226 | SAN | I/C |
| Quetiapine | 200mg tablet | 02353199 | 1.8527 | SAN | I/C |
| Quetiapine | 300mg tablet | 02353202 | 2.7038 | SAN | I/C |
| *Risedronate sodium | | | | | |
| Apo-Risedronate | 35mg tablet | 02353687 | 4.8575 | APX | I/C EDS |
| pms-Risedronate | 35mg tablet | 02302209 | 4.8575 | PMS | I/C EDS |
| ratio-Risedronate | 35mg tablet | 02319861 | 4.8575 | RPH | I/C EDS |
| Sandoz Risedronate | 35mg tablet | 02327295 | 4.8575 | SDZ | I/C EDS |
| *Ropinirole HCl | | | | | |
| Jamp-Ropinirole | 0.25mg tablet | 02352338 | 0.1419 | JPC | I/C |
| Jamp-Ropinirole | Img tablet | 02352346 | 0.5676 | JPC | I/C |
| Jamp-Ropinirole | 2mg tablet | 02352354 | 0.6244 | JPC | I/C |
| Jamp-Ropinirole | 5mg tablet | 02352362 | 1.7192 | JPC | I/C |
| Ropinirole | 0.25mg tablet | 02353040 | 0.1419 | SAN | I/C |
| Ropinirole | Img tablet | 02353059 | 0.5676 | SAN | I/C |
| Ropinirole | 2mg tablet | 02353067 | 0.6244 | SAN | I/C |
| Ropinirole | 5mg tablet | 02353075 | 1.7192 | SAN | I/C |
| *Sumatriptan | | | | | |
| Sumatriptan | 25mg tablet | 02286513 | 8.9900 | SAN | I/C EDS |
| Sumatriptan | 50mg tablet | 02286521 | 9.0650 | SAN | I/C EDS |
| Sumatriptan | 100mg tablet | 02286548 | 9.9867 | SAN | I/C EDS |
| *Tamsulosin HCl | | | | | |
| Jamp-Tamsulosin | 0.4mg SR capsule | 02352419 | 0.6000 | JPC | I/C (with generics) |
| *Tamsulosin HCl | | | | No | ot I/C with FlomaxCR |
| Sandoz Tamsulosin | 0.4mg SR capsule | 02295121 | 0.4500 | SDZ | I/C with FlomaxCR |
| *Valacyclovir | | | | | |
| CO Valacyclovir | 500mg tablet | 02331748 | 2.5443 | COB | I/C |
| *Venlafaxine HCl | | | | | |
| Venlafaxine XR | 37.5mg XR capsule | 02354713 | 0.5879 | SAN | I/C |
| Venlafaxine XR | 75mg XR capsule | 02354721 | 1.1758 | SAN | I/C |
| Venlafaxine XR | 150mg XR capsule | 02354748 | 1.2414 | SAN | I/C |
| *Warfarin | | | | | |
| Warfarin | 1mg tablet | 02344025 | 0.1782 | SAN | I/C |
| Warfarin | 2mg tablet | 02344033 | 0.1885 | SAN | I/C |
| TY GILLGIA | | | | | I/C |
| | 2.5mg tablet | 02344041 | 0.1509 | SAN | 1/0 |
| Warfarin | | 02344041 02344068 | 0.1309 | SAN | I/C |
| Warfarin Warfarin | 2.5mg tablet | | | | |
| Warfarin Warfarin Warfarin Warfarin Warfarin | 2.5mg tablet 3mg tablet | 02344068 | 0.2337 | SAN | I/C |

Effective November 1, 2010, the following products will be listed as benefits in Saskatchewan:

| Darunavir Prezista | 75mg tablet | 02338432 | 1.8644 | JAN | EDS |
|--|-------------------------------------|----------|---------|-----|-----|
| Dorzolamide HCl/Timolo Cosopt Preservative Free | l maleate (Pkg) 2%/0.5 % oph sol | 02258691 | 30.8300 | MSD | |
| Morphine Kadian | 10mg SR tablet | 02242163 | 0.3911 | ABB | |

Exception Drug Status (EDS) Criteria

To access the criteria for drugs listed under the EDS program, please refer to the Saskatchewan Formulary available in print or online at http://formulary.drugplan.health.gov.sk.ca/.

DRUG PLAN & EXTENDED BENEFITS HOLIDAY HOURS

Please note the office is closed on the following dates: MONDAY, OCTOBER 11, 2010 and THURSDAY, NOVEMBER 11, 2010

